Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MRVI Stock Summary
Top 10 Correlated ETFs
MRVI
In the News

Maravai LifeSciences Announces November 2023 Investor Conference Schedule
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023
SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2023 Earnings Call Transcript August 7, 2023 5:00 PM ET Company Participants Debra Hart - Head of IR Carl Hull - Executive Chairman of the Board Trey Martin - CEO Kevin Herde - CFO Becky Buzzeo - CCO Drew Burch - EVP, and GM Nucleic Acid Production Conference Call Participants Matt Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Dan Leonard - Credit Suisse Catherine Schulte - Baird Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Madeline Mollman - William Blair John Sourbeer - UBS Operator Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Drew Burch - EVP, Nucleic Acid Production Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Robert W. Baird Matthew Sykes - Goldman Sachs Daniel Leonard - Credit Suisse Daniel Arias - Stifel John Sourbeer - UBS Tejas Savant - Morgan Stanley Operator Good afternoon.

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.54 per share a year ago.

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 8, 2023
SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2023 financial and operating results after the market closes on Monday, May 8, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

2 Top Biotech Stocks to Buy In March and Hold Forever
Long-term investments in biotech tend to be hard to come by. Moderna's gargantuan pipeline means that it has a very long growth runway ahead.

Maravai LifeSciences Announces March 2023 Investor Conference Schedule
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.
MRVI Financial details
MRVI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.39 | 1.61 | 27.45 | 6.96 | 6.71 | |
Net income per share | -0.2 | -0.06 | 8.6 | 4.09 | 3.73 | |
Operating cash flow per share | 0 | 0.27 | 14.7 | 3.21 | 4.07 | |
Free cash flow per share | -0.04 | 0.08 | 12.25 | 3.08 | 3.94 | |
Cash per share | 0.25 | 0.28 | 22.82 | 4.8 | 4.81 | |
Book value per share | 1.62 | 1.59 | 8.55 | 2.75 | 4.14 | |
Tangible book value per share | -3.31 | -3.12 | -23.88 | 2.4 | 3.08 | |
Share holders equity per share | 1.62 | 1.59 | 8.55 | 2.75 | 4.14 | |
Interest debt per share | 4.13 | 4.72 | 60.04 | 4.92 | 4.6 | |
Market cap | 2.66B | 2.66B | 290.35M | 4.81B | 1.88B | |
Enterprise value | 2.97B | 3.02B | 644.94M | 4.79B | 1.84B | |
P/E ratio | -149.77 | -510.6 | 3.26 | 10.25 | 3.84 | |
Price to sales ratio | 21.45 | 18.55 | 1.02 | 6.02 | 2.13 | |
POCF ratio | -14.28K | 110.12 | 1.91 | 13.05 | 3.51 | |
PFCF ratio | -699.4 | 381.17 | 2.29 | 13.6 | 3.63 | |
P/B Ratio | 18.39 | 18.78 | 3.28 | 15.24 | 3.45 | |
PTB ratio | 18.39 | 18.78 | 3.28 | 15.24 | 3.45 | |
EV to sales | 24.01 | 21.11 | 2.27 | 6 | 2.08 | |
Enterprise value over EBITDA | 74.7 | 62.28 | 6.9 | 8.82 | 3.23 | |
EV to operating cash flow | -15.99K | 125.28 | 4.24 | 13 | 3.42 | |
EV to free cash flow | -783.16 | 433.63 | 5.09 | 13.55 | 3.54 | |
Earnings yield | -0.01 | 0 | 0.31 | 0.1 | 0.26 | |
Free cash flow yield | 0 | 0 | 0.44 | 0.07 | 0.28 | |
Debt to equity | 2.35 | 2.76 | 6.67 | 1.69 | 1.07 | |
Debt to assets | 0.63 | 0.68 | 0.46 | 0.28 | 0.26 | |
Net debt to EBITDA | 7.99 | 7.53 | 3.8 | -0.03 | -0.08 | |
Current ratio | 1.5 | 2.05 | 2.54 | 7.89 | 7.7 | |
Interest coverage | 0.6 | 0.8 | 2.2 | 18.33 | 28.13 | |
Income quality | 0.01 | -4.64 | 1.93 | 0.79 | 1.09 | |
Dividend Yield | 0.02 | 0 | 2.1 | 0 | 0 | |
Payout ratio | -2.94 | 0 | 6.85 | 0 | 0 | |
Sales general and administrative to revenue | 0.33 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | |
Intangibles to total assets | 0.82 | 0.73 | 0.32 | 0.14 | 0.22 | |
Capex to operating cash flow | 19.41 | -0.71 | -0.17 | -0.04 | -0.03 | |
Capex to revenue | -0.03 | -0.12 | -0.09 | -0.02 | -0.02 | |
Capex to depreciation | -0.16 | -0.71 | -0.98 | -0.6 | -0.45 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.09 | 0.01 | 0.02 | |
Graham number | 2.7 | 1.45 | 40.67 | 15.9 | 18.65 | |
ROIC | 0.03 | 0.04 | 0.09 | 0.57 | 0.43 | |
Return on tangible assets | -0.18 | -0.03 | 0.1 | 0.28 | 0.28 | |
Graham Net | -3.94 | -4.36 | -79.69 | -6.17 | -4.66 | |
Working capital | 17.88M | 30.99M | 200.82M | 646.26M | 737.76M | |
Tangible asset value | -294.39M | -277.5M | -247.19M | 275.02M | 404.91M | |
Net current asset value | -337.86M | -372.62M | -784.35M | -632.88M | -529.17M | |
Invested capital | 2.35 | 2.76 | 6.67 | 1.69 | 1.07 | |
Average receivables | 0 | 17.01M | 34.52M | 84.27M | 132.16M | |
Average payables | 0 | 5.54M | 7.82M | 8.16M | 7.07M | |
Average inventory | 0 | 14.26M | 23.75M | 42.43M | 47.35M | |
Days sales outstanding | 47.13 | 45.98 | 65.55 | 53.67 | 60.69 | |
Days payables outstanding | 21.65 | 40.83 | 37.44 | 21.17 | 12.94 | |
Days of inventory on hand | 85.94 | 77.54 | 152.61 | 133.88 | 93.22 | |
Receivables turnover | 7.74 | 7.94 | 5.57 | 6.8 | 6.01 | |
Payables turnover | 16.86 | 8.94 | 9.75 | 17.24 | 28.2 | |
Inventory turnover | 4.25 | 4.71 | 2.39 | 2.73 | 3.92 | |
ROE | -0.12 | -0.04 | 1.01 | 1.49 | 0.9 | |
Capex per share | -0.04 | -0.19 | -2.45 | -0.13 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.45 | 1.56 | 0.6 | 0.52 | 0.51 | |
Net income per share | 0.76 | 0.66 | -0.01 | -0.05 | -0.05 | |
Operating cash flow per share | 0.84 | 0.75 | 0.65 | 0.15 | 0 | |
Free cash flow per share | 0.79 | 0.71 | 0.59 | -0.04 | 0 | |
Cash per share | 4.69 | 4.8 | 4.77 | 4.4 | 4.39 | |
Book value per share | 3.83 | 4.14 | 3.96 | 3.95 | 3.94 | |
Tangible book value per share | 2.55 | 3.08 | 2.52 | 2.55 | 2.56 | |
Share holders equity per share | 3.83 | 4.14 | 3.96 | 3.95 | 3.94 | |
Interest debt per share | 4.08 | 4.52 | 4.77 | 4.73 | 4.31 | |
Market cap | 3.36B | 1.88B | 1.85B | 1.64B | 1.32B | |
Enterprise value | 3.27B | 1.84B | 1.83B | 1.68B | 1.3B | |
P/E ratio | 8.42 | 5.39 | -342.3 | -62.65 | -51.04 | |
Price to sales ratio | 17.56 | 9.2 | 23.36 | 23.78 | 19.73 | |
POCF ratio | 30.51 | 18.96 | 21.69 | 85.39 | 0 | |
PFCF ratio | 32.42 | 20.23 | 23.91 | -279.47 | 0 | |
P/B Ratio | 6.67 | 3.45 | 3.54 | 3.15 | 2.54 | |
PTB ratio | 6.67 | 3.45 | 3.54 | 3.15 | 2.54 | |
EV to sales | 17.12 | 8.97 | 23.2 | 24.32 | 19.4 | |
Enterprise value over EBITDA | 28.01 | 16.33 | 209.66 | -191.36 | -234.43 | |
EV to operating cash flow | 29.76 | 18.49 | 21.55 | 87.33 | 0 | |
EV to free cash flow | 31.61 | 19.72 | 23.75 | -285.79 | 0 | |
Earnings yield | 0.03 | 0.05 | 0 | 0 | 0 | |
Free cash flow yield | 0.03 | 0.05 | 0.04 | 0 | 0 | |
Debt to equity | 1.06 | 1.07 | 1.18 | 1.19 | 1.07 | |
Debt to assets | 0.24 | 0.26 | 0.27 | 0.27 | 0.25 | |
Net debt to EBITDA | -0.71 | -0.42 | -1.37 | -4.23 | 3.97 | |
Current ratio | 7.22 | 7.7 | 6.13 | 9.33 | 8.96 | |
Interest coverage | 37.28 | 10.73 | -0.18 | -1.65 | -1.32 | |
Income quality | 1.1 | 1.14 | -63.11 | -1.61 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.03 | 0.02 | 0.05 | 0.06 | 0.07 | |
Intangibles to total assets | 0.23 | 0.22 | 0.25 | 0.25 | 0.24 | |
Capex to operating cash flow | -0.06 | -0.06 | -0.09 | -1.31 | 0 | |
Capex to revenue | -0.03 | -0.03 | -0.1 | -0.36 | 0 | |
Capex to depreciation | -0.65 | -0.62 | -0.72 | -2.12 | 0 | |
Stock based compensation to revenue | 0.02 | 0.03 | 0.08 | 0.13 | 0 | |
Graham number | 8.08 | 7.87 | 0.95 | 2.1 | 2.08 | |
ROIC | 0.1 | 0.08 | 0 | -0.01 | -0.01 | |
Return on tangible assets | 0.06 | 0.05 | 0 | 0 | 0 | |
Graham Net | -5.01 | -4.66 | -5.44 | -5.51 | -1.71 | |
Working capital | 719.87M | 737.76M | 640.62M | 624.39M | 622.61M | |
Tangible asset value | 335.24M | 404.91M | 332.49M | 336.45M | 338.4M | |
Net current asset value | -571.7M | -529.17M | -649.24M | -667.49M | -674.41M | |
Invested capital | 1.06 | 1.07 | 1.18 | 1.19 | 1.07 | |
Average receivables | 130.58M | 139.52M | 101.85M | 53.05M | 388.41M | |
Average payables | 16.36M | 7.73M | 5.39M | 5.72M | 8.04M | |
Average inventory | 61.27M | 52.79M | 48.99M | 51.11M | 48.27M | |
Days sales outstanding | 62.22 | 64.55 | 64.79 | 64.28 | 979.35 | |
Days payables outstanding | 22.3 | 10.13 | 12.79 | 13.85 | 23.12 | |
Days of inventory on hand | 147.16 | 72.93 | 146.51 | 98.59 | 120.56 | |
Receivables turnover | 1.45 | 1.39 | 1.39 | 1.4 | 0.09 | |
Payables turnover | 4.04 | 8.89 | 7.04 | 6.5 | 3.89 | |
Inventory turnover | 0.61 | 1.23 | 0.61 | 0.91 | 0.75 | |
ROE | 0.2 | 0.16 | 0 | -0.01 | -0.01 | |
Capex per share | -0.05 | -0.05 | -0.06 | -0.19 | 0 |
MRVI Frequently Asked Questions
What is Maravai LifeSciences Holdings, Inc. stock symbol ?
Maravai LifeSciences Holdings, Inc. is a US stock , located in San diego of Ca and trading under the symbol MRVI
Is Maravai LifeSciences Holdings, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $23.5. The lowest prediction is $22 and the highest is $25
What is MRVI stock prediction ?
What is Maravai LifeSciences Holdings, Inc. stock quote today ?
Maravai LifeSciences Holdings, Inc. stock price is $5.175 today.
Is Maravai LifeSciences Holdings, Inc. stock public?
Yes, Maravai LifeSciences Holdings, Inc. is a publicly traded company.